NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy
Tuesday, July 28, 2026 1 min read
Key Takeaway: NeuroPace, Inc. has received FDA guidance regarding its Premarket Approval Panel Track Supplement. This supplement aims to expand the indication of the RNS® System to include patients suffering from antiseizure medication-resistant idiopathic generalized epilepsy (IGE). The communication from the FDA suggests a positive direction in the review process.
Market Sentiment Analysis
POSITIVE FACTORS
NeuroPace is expanding its indication for the RNS® System.
The FDA communication indicates progress in the review process.
This expansion could benefit patients with medication-resistant epilepsy.
Full Press Release Details
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today provided an update on the U.S. Food and Drug Administration review of the Company’s Premarket Approval Panel Track Supplement seeking to expand the labeled indication for the RNS® System to include patients with antiseizure medication-resistant idiopathic generalized epilepsy (IGE). NeuroPace has received a communication from FD
Frequently Asked Questions
What is the purpose of NeuroPace's PMA Supplement?
The PMA Supplement aims to expand the RNS® System's indication for patients with medication-resistant idiopathic generalized epilepsy.
What communication did NeuroPace receive from the FDA?
NeuroPace received guidance from the FDA regarding the review of their indication expansion.
Who could benefit from the RNS® System expansion?
Patients with antiseizure medication-resistant idiopathic generalized epilepsy may benefit from the expansion.